Europe syndromic multiplex diagnostic refers to cutting-edge medical technology and methodologies employed within Europe for detecting, diagnosing, and monitoring various syndromes and diseases using multiplex diagnostic platforms. This approach combines multiple tests into a single comprehensive assay, enabling the simultaneous detection of a wide range of pathogens or disease markers in a single sample. Their continuous evolution and application in clinical settings highlight their significance in improving patient outcomes and the overall healthcare landscape.
Access Full Reports@ https://www.databridgemarketresearch.com/pt/reports/europe-syndromic-multiplex-diagnostic-market
Data Bridge Market Research analyses that the Europe Syndromic Multiplex Diagnostic Market, which was USD 3,879.99 million in 2022, is expected to reach USD 7,562.53 million by 2030, at a CAGR of 8.7% during the forecast period 2023 to 2030. The increasing prevalence of infectious diseases drives the syndromic multiplex diagnostic market, offering rapid identification for early treatment and improved outcomes. Growing demand for accurate and swift tests and evolving multiplexing technologies allow simultaneous testing for multiple pathogens, enhancing diagnosis accuracy and speed.
Key Findings of the Study
Rising diagnostic healthcare expenditure is expected to drive the market's growth rate
Elevated healthcare expenditure is a pivotal catalyst for the syndromic multiplex diagnostic market's expansion. With increased financial resources allocated to healthcare, patients gain improved access to advanced and precise diagnostic services, enhancing their disease management capabilities. This financial support bolsters the availability and affordability of diagnostic services, ultimately benefiting patients and the healthcare industry as a whole. Consequently, higher healthcare spending acts as a positive force propelling the growth of the syndromic multiplex diagnostic market, fostering innovation and improved patient care.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product and Services (Reagents and Consumables, Instruments, Software, and Accessories and Services), Infection Type (Viral, Bacterial, Parasites, and Fungal), Disease (Respiratory Infections, Gastroenteritis, Sexually Transmitted Infections, Sepsis, Meningitis, and Others), Panels Type (Respiratory Panel, GI-Enteric Panel, Sexually Transmitted Disease Panel, Blood-Sepsis Panel, Meningitis Panel, and Others), End User (Clinical Laboratories, Hospitals, Pharmaceutical, and Biotechnology Companies, Research Institutes and Others)
|
|
Countries Covered
|
Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe
|
|
Market Players Covered
|
Seegene Inc. (South Korea), Luminex Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), BD (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher (U.S.), QIAGEN (Germany), Abbott (U.S.), Hologic, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Siemens Healthcare GmbH (Germany), Biocartis (Belgium), QuantuMDx Group Ltd. (U.K.), Bosch Healthcare Solutions GmbH (Germany), Prominex Inc. (U.S.), Curetis (Germany)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The Europe syndromic multiplex diagnostic market is segmented on the basis of product and services, infection type, disease, panels type, and end user.
- On the basis of product and services, the Europe syndromic multiplex diagnostic market is segmented into reagents and consumables, instruments, software, and accessories and services
- On the basis of infection type, the Europe syndromic multiplex diagnostic market is segmented into viral, bacterial, parasites, and fungal
- On the basis of disease, the Europe syndromic multiplex diagnostic market is segmented into respiratory infections, gastroenteritis, sexually transmitted infections, sepsis, meningitis, and others
- On the basis of panels type, the Europe syndromic multiplex diagnostic market is segmented into respiratory panel, GI-enteric panel, sexually transmitted disease panel, blood-sepsis panel, meningitis panel, and others
- On the basis of end user, the Europe syndromic multiplex diagnostic market is segmented into clinical laboratories, hospitals, pharmaceutical and biotechnology companies, research institutes, and others
Major Players
Data Bridge Market Research recognizes the following companies as the major Europe syndromic multiplex diagnostic market players in Europe syndromic multiplex diagnostic market are Seegene Inc. (South Korea), Luminex Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), BD (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher (U.S.), QIAGEN (Germany), Abbott (U.S.), Hologic, Inc. (U.S.).
Market Developments
- In 2022, Cipla commercially launched the RT-Direct multiplex COVID-19 RT-PCR test kit in India, winning a partnership with Genese2Me Pvt Ltd. This test kit is able to detect multiple strains of COVID-19, including the Omicron variant. The COVID-19 pandemic has led to a global shortage of syndromic multiplex diagnostic tests. This has created an opportunity for new players in the market, such as Cipla and Hologic
- In 2021, Hologic launched the Novodiag System in Europe. Novodiag is a fully automated molecular diagnostic solution for on-demand infectious diseases and antimicrobial resistance testing. This system can test for multiple pathogens in a single sample, which can help to save time and resources. The development of new multiplexing technologies is also driving market growth. These technologies make it possible to test for multiple pathogens in a single sample, improving the accuracy and speed of diagnosis
- In 2021, Eurofins launched a multiplex PCR Assay to rapidly detect the B.1.617 SARS-CoV-2 variant. This assay can detect the variant in as little as 24 hours, which can help to speed up the diagnosis and treatment of patients. The increasing prevalence of infectious diseases is another factor driving market growth. As the world's population grows and ages, the risk of infectious diseases also increases
- In 2020, BD's attainment of Emergency Use Authorization (EUA) from the US FDA for an additional COVID-19 molecular diagnostic test, along with CE marking for the IVD Directive (98/79/EC), significantly bolstered the company's market credibility. This regulatory approval showcased their commitment to addressing the pandemic's diagnostic needs. It underscored their adherence to rigorous quality and safety standards, instilling confidence among healthcare professionals and the broader market, further solidifying BD's reputation in the medical diagnostics industry
Regional Analysis
Geographically, the countries covered in the Europe syndromic multiplex diagnostic market report are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.
As per Data Bridge Market Research analysis:
Germany is estimated to be the fastest-growing region in Europe syndromic multiplex diagnostic market in the forecast period 2023 - 2030
Germany is expected to dominate the Europe syndromic multiplex diagnostic market, driven by a significant rise in infectious disease prevalence. The demand for efficient and rapid diagnostic solutions has increased as these diseases become more prevalent. Syndromic multiplex diagnostics offer the ability to swiftly and accurately identify the causes of infections, enabling early and targeted treatment. This surge in demand for such diagnostic tools is expected to fuel market expansion, ultimately contributing to improved disease management and better patient outcomes in Germany.
For more detailed information about the Europe syndromic multiplex diagnostic market report, click here – https://www.databridgemarketresearch.com/pt/reports/europe-syndromic-multiplex-diagnostic-market
